Cartalax Peptide: Benefits, Russian Human Data & Cartilage Research Guide (2026)

Cartalax is a synthetic tripeptide bioregulator with the amino acid sequence Ala-Glu-Asp (AED), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Classified as a cartilage-specific peptide, Cartalax works by activating gene expression in chondrocytes — the cells responsible for producing and maintaining cartilage — while simultaneously reducing the enzymes that break cartilage down. It has been marketed in Russia for over 40 years under that country's supplement framework and is available in the United States only as a research chemical. The Cartalax blend is available at Blue Ridge Peptides.

What Is Cartalax (AED Peptide)?

Cartalax — also known as the AED peptide — is a three-amino-acid peptide (Alanine-Glutamate-Aspartate) belonging to a class of compounds called short peptide bioregulators. These are ultra-small peptides designed to interact directly with DNA and restore age-related changes in gene expression inside specific tissues.

Who Developed It and Where Did It Come From?

Cartalax was developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Khavinson's group created a series of tissue-specific short peptide bioregulators — Cartalax (cartilage), Epitalon (pineal gland), Cardiogen (heart), Pinealon (brain) — based on the theory that short peptides derived from specific tissues can restore age-related gene expression changes in those same tissues.

How Is It Different From Other Healing Peptides?

Most well-known research peptides — BPC-157, TB-500, GHK-Cu — work broadly across many tissue types. Cartalax is different: it is cartilage-specific. It operates at the level of chondrocyte gene expression, targeting the genetic program that controls cartilage matrix production, chondrocyte survival, and joint inflammation — rather than acting as a general-purpose repair signal.

What Country Is Cartalax Approved In?

Cartalax is sold as a dietary supplement in Russia, where it was developed. It is not approved for human or veterinary use in the United States, Europe, and is classified as a research chemical in most Western countries including the US, Canada, Australia, and the UK. No Phase I, II, or III clinical trials have been registered on ClinicalTrials.gov. Everywhere it is sold in the West, it is sold strictly for laboratory research — not for human use.

How Cartalax Works: The Cartilage Mechanism Explained

Cartalax works at the level of gene expression inside chondrocytes. Here's what the research shows, mechanism by mechanism:

1. It Activates SOX9 — The Cartilage Construction Master Switch

SOX9 is the master transcription factor that switches on the genes responsible for producing type II collagen and aggrecan — the structural proteins of healthy cartilage. Research shows Cartalax upregulates SOX9 expression in chondrocytes, effectively turning the cartilage-building program back on.

2. It Boosts Chondrocyte Proliferation 1.4–2.1x

In cell culture studies, Cartalax increased chondrocyte proliferation by 1.4 to 2.1 times baseline — meaning more cartilage-producing cells are available to maintain and rebuild the cartilage matrix.

3. It Shuts Down MMP-3, MMP-13, and ADAMTS-5

MMP-3, MMP-13, and ADAMTS-5 are the enzymes that actively degrade cartilage. Cartalax reduces their expression, slowing the breakdown side of the cartilage equation while the building side ramps up.

4. It Reduces Joint Inflammation at the Cellular Level

Cartalax suppresses NF-κB, IL-1β, and TNF-α inflammatory signaling in joint tissue — the same inflammatory cascade that drives cartilage destruction in osteoarthritis.

5. It Keeps Cartilage Cells Alive Longer (Anti-Apoptotic)

By upregulating Bcl-2 anti-apoptotic proteins, Cartalax promotes chondrocyte survival — keeping cartilage cells alive and functional longer instead of letting them die off with age.

6. It Reduces Cellular Aging Markers in Joint Tissue

Cartalax reduces cellular senescence markers p16, p21, and p53 while increasing SIRT-6 — a longevity-associated protein. In plain terms: it appears to make old cartilage cells behave more like young ones.

Cartalax Benefits — What the Research Shows

Across preclinical and observational research, Cartalax has shown the following effects:

• Activates SOX9 and type II collagen gene expression in chondrocytes
• Increases chondrocyte proliferation 1.4–2.1x in cell culture
• Reduces MMP-3, MMP-13, and ADAMTS-5 — the enzymes that degrade cartilage
• Suppresses NF-κB, IL-1β, and TNF-α inflammatory signaling in joint tissue
• Promotes anti-apoptotic signaling (Bcl-2) to keep cartilage cells alive longer
• Reduces cellular senescence markers p16, p21, and p53 while increasing SIRT-6

Russian observational data reports 20–40% pain reduction and 15–30% mobility improvement in knee osteoarthritis patients, as findings in reported studies. Note: no registered controlled clinical trials exist.

The Russian Human Data: What Actually Happened in Real People

This is the unique angle on Cartalax — unlike most research peptides, there is actual human data. It comes from three sources, and each needs honest framing:

Study 1: Patent Study RU2299741C1 (29 Patients, Knee OA)

A Khavinson group study embedded in Russian Patent RU2299741C1 treated 29 knee osteoarthritis patients with intramuscular Cartalax for 20 days. Reported results: 54.5–62.7% improvement in pain and mobility. The honest caveats: no radiographic improvement was observed, no p-values were published, and no adverse event table was included.

Study 2: St. Petersburg Institute Observational Data

Observational data from the St. Petersburg Institute reports that Cartalax relieved pain in 68% of knee osteoarthritis patients and 53% of spondylarthrosis patients, with some imaging signs of cartilage improvement.

Study 3: Broader Russian Observational Reports (20–40 Years of Data)

Broader Russian observational reports across decades of use describe OA patients experiencing 20–40% pain reduction and 15–30% mobility improvement over a 2–6 month observation period in the reported data.

The Honest Assessment

None of these are registered randomized controlled trials. The data is real, it's human, and it spans decades — but it is observational and patent-embedded, not gold-standard clinical evidence. The mechanism research is strong; the human data is promising but limited. Any source claiming Cartalax is a "proven" treatment is overstating the evidence.

Cartilage Volume Loss Per Year: What the Data Shows

Cartilage Volume Loss in Healthy Adults

According to published MRI studies, healthy aging adults lose an average of 1.2% of tibial cartilage volume per year (10.7-year longitudinal cohort study, Arthritis Research & Therapy, 2019). Cartilage loss was observed in 100% of study participants — it is a universal aspect of aging.

Cartilage Volume Loss With Osteoarthritis

In people with diagnosed knee osteoarthritis, the rate accelerates to approximately 3.7–4.4% per year (MRI study, 4.5 years).

Femoral Cartilage by Age Group

MRI data shows women aged 50–78 have approximately 21% less femoral cartilage than women aged 20–30, while men in the same age range have approximately 13% less.

Collagen Loss by Age — The Numbers

The Collagen Timeline: Decade by Decade

Collagen production begins to decline around age 25 at approximately 1–1.5% per year. Research published in the American Journal of Pathology (Varani et al., 2006) found that natural collagen secretion decreases by 38% from age 25 to age 80. By age 35, most people have approximately 15% less collagen than at their peak. By age 50, the loss reaches 25–30%.

The Menopause Acceleration

For women, menopause accelerates the decline significantly — some studies report up to 30% collagen loss in the first five years of menopause alone, followed by an ongoing decline of approximately 2% per year.

How Prevalent Is Joint Disease? Global and U.S. Statistics

According to the Global Burden of Disease Study 2021, approximately 607 million people worldwide had osteoarthritis in 2021 — 7.7% of the global population, a 132.2% increase in total cases since 1990. In the United States, OA affects over 34 million adults and costs over $136 billion annually. Cases of knee osteoarthritis are projected to increase by 74.9% by 2050. The United States has the highest age-standardized rate of OA in young adults aged 30–44 worldwide.

Cartalax vs BPC-157: What's the Difference?

Cartalax and BPC-157 address joint health through different mechanisms. BPC-157 works primarily through angiogenesis (new blood vessel formation), growth factor upregulation, and broad-spectrum tissue repair across tendons, ligaments, gut, and nerves — see my BPC-157 guide for the full breakdown. Cartalax is cartilage-specific — it operates at the level of chondrocyte gene expression, directly restoring the genetic program that controls cartilage matrix production, chondrocyte survival, and joint inflammation. Many researchers combine both compounds in joint-related research protocols: BPC-157 for the healing environment, Cartalax for the cartilage cell program. The Wolverine Blend (BPC-157 + TB-500) is another common tissue-repair research combination worth reading about.

What the Research Timeline Looks Like

Based on the Russian observational data, reported effects on pain and mobility in OA patients appeared after 2–6 months in the reported studies — not days or weeks. Cartilage biology is slow: chondrocytes turn over gradually, and matrix remodeling takes months. Any laboratory research protocol design should account for that timeframe, and no outcome is guaranteed given the absence of controlled human trials.

All figures described here come from published observational literature conducted by third parties. They are reported as research findings, not as anticipated outcomes, and nothing in this article describes or suggests use in humans.

Where to Find Cartalax — Three Partner Options

Cartalax shows up in the research market in two forms: as a standalone compound, and inside combination blends paired with other tissue-repair peptides. Here's where each is listed among our partners. The universal code PEPHUB applies at all three.

Blue Ridge Peptides — the standalone Cartalax blend. If a research application calls for Cartalax on its own, without other compounds in the vial, this is the listing. Useful for research isolating Cartalax's mechanisms specifically.

Petratide Science — Cartalax + BPC-157 + TB-500. The widest combination of the three. Pairs the cartilage-specific chondrocyte signaling of Cartalax with BPC-157's angiogenesis pathway and TB-500's actin-regulation and cell-migration profile. See theWolverine Blend breakdown for more on how BPC-157 and TB-500 are studied together.

True Amino Labs — Cartalax + BPC-157. A two-compound pairing. Cartalax working at the chondrocyte gene-expression level, BPC-157 working on the vascular and growth-factor side. See theBPC-157 guide for the full research picture on that compound.

These partners are listed in no particular order and are not ranked, scored, or compared. Every listing is research-use-only. Verify the batch-specific COA before any laboratory work.

What to Look for in a COA

Always verify a Certificate of Analysis (COA) showing third-party HPLC testing at ≥98% purity before purchasing any research peptide. My COA Guide walks through exactly what to look for — identity vs. purity, overfill, and red flags. And if you're reconstituting a lyophilized vial, the Reconstitution Calculator does the math for you.

Frequently Asked Questions About Cartalax

What is Cartalax peptide?

Cartalax is a synthetic tripeptide bioregulator with the amino acid sequence Ala-Glu-Asp (AED). Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, it is designed to target gene expression in chondrocytes — the cells responsible for producing and maintaining cartilage.

What country is Cartalax approved in?

Cartalax is sold as a dietary supplement in Russia. It is not approved for human or veterinary use in the United States, Europe, and is classified as a research chemical in most Western countries including the US, Canada, Australia, and the UK.

Is Cartalax approved for human use?

No. Cartalax (AED peptide) is not approved for human or veterinary use anywhere in the West. No Phase I, II, or III clinical trials have been registered on ClinicalTrials.gov. All available human data comes from Russian observational studies and a patent-embedded unregistered study (RU2299741C1).

What does Cartalax do for cartilage?

It activates genes responsible for collagen type II and aggrecan synthesis while reducing the activity of MMP-3, MMP-13, and ADAMTS-5 — enzymes that break cartilage down. It also suppresses inflammatory signals (NF-κB, IL-1β, TNF-α) and promotes chondrocyte survival via Bcl-2. The overall effect is a shift toward cartilage matrix building and away from cartilage breakdown.

How does Cartalax compare to BPC-157 for joints?

BPC-157 works through angiogenesis and broad tissue repair; Cartalax is cartilage-specific and works through chondrocyte gene expression. Many researchers combine both: BPC-157 for the healing environment, Cartalax for the cartilage cell program.

What is the AED peptide?

AED peptide is another name for Cartalax. AED stands for Alanine-Glutamate-Aspartate, the three-amino-acid sequence that makes up the Cartalax tripeptide.

How much cartilage is lost per year, according to the research?

Healthy aging adults lose about 1.2% of tibial cartilage volume per year on average. In knee osteoarthritis, that accelerates to roughly 3.7–4.4% per year. Cartilage loss was observed in 100% of studied participants — it's a universal part of aging.

When does collagen production start to decline?

Around age 25, at roughly 1–1.5% per year. Collagen secretion drops 38% from age 25 to 80, and menopause can accelerate the loss to as much as 30% in the first five years.

How prevalent is osteoarthritis?

About 607 million people worldwide had osteoarthritis in 2021 (7.7% of the global population), a 132.2% increase since 1990. Knee OA cases are projected to rise 74.9% by 2050.

Where can I buy Cartalax?

Cartalax is listed at three Research Pep Hub partners, in two forms.Blue Ridge Peptides carries the standalone Cartalax blend.Petratide Science carries Cartalax combined with BPC-157 and TB-500.True Amino Labs carries Cartalax combined with BPC-157. The universal code PEPHUB applies at all three. Always verify a third-party HPLC COA at 98% purity or higher. Cartalax is sold for research purposes only and is not approved for human use.

Who developed Cartalax?

Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, as part of a series of tissue-specific bioregulatory peptides including Epitalon, Cardiogen, and Pinealon.

What does the Russian human data show for Cartalax?

Three sources: the RU2299741C1 patent study (29 knee OA patients, 54.5–62.7% improvement in pain and mobility), St. Petersburg Institute observational data (68% pain relief in knee OA patients), and broader Russian observational reports (20–40% pain reduction, 15–30% mobility improvement over 2–6 months). None are registered randomized controlled trials.

What peptides are blended with Cartalax?

Cartalax is most commonly combined with other tissue-repair research peptides. Petratide Science offers a Cartalax blend with BPC-157 and TB-500. True Amino Labs offers a Cartalax blend with BPC-157. Blue Ridge Peptides offers Cartalax as a standalone blend. The rationale for combining them is mechanistic: Cartalax acts on chondrocyte gene expression specific to cartilage, BPC-157 acts through angiogenesis and growth-factor signaling, and TB-500 acts on actin regulation and cell migration. All are research-use-only compounds not approved for human use.

Research Citations and Sources

• Ashapkin V et al. (2020) — Gene expression in human MSC aging cultures, Molecular Biology Reports
• Global Burden of Osteoarthritis 1990–2020, GBD 2021 Study — The Lancet Rheumatology (2023)
• Association of age, sex and BMI with tibial cartilage volume loss — Arthritis Research & Therapy (2019)
• Knee OA cartilage loss 4.5-year MRI study
• Varani J et al. (2006) — Decreased collagen production in chronologically aged skin, Am J Pathol (PMID: 16741243)
• OA and estrogen — Nature (2025)
• Russian Patent RU2299741C1 — Cartalax (AED) human knee OA study, Khavinson group
• Myakisheva SN et al. — Chondrocyte peptide bioregulation (2023), Bulletin of Experimental Biology and Medicine

Related Articles

• BPC-157: The Complete Research Guide
• GHK-Cu Copper Peptide: Complete Guide
• The Wolverine Blend: BPC-157 + TB-500
• Zen Blend Review

About the Author: PepHub has spent years researching the peptide space, reviewing vendor COAs, and translating complex research into plain-language guides. ResearchPepHub.com is an affiliate-supported education hub — we earn commissions on purchases made through our links at no additional cost to the reader. We are not doctors and this content is not medical advice. Cartalax is a research chemical not approved for human use.

Last updated: October 2026 · Research data current as of Q4 2026.

Tags: Cartalax, AED peptide, cartilage bioregulator, Khavinson, chondrocytes, SOX9, type II collagen, osteoarthritis, joint health, Russian bioregulator